CY2022003I1 - Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις των σχετικων me janus (ιανος) kinασων (jak) - Google Patents

Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις των σχετικων me janus (ιανος) kinασων (jak)

Info

Publication number: CY2022003I1
Authority: CY; Cyprus
Prior art keywords: janus; jak; pyrrolo; inhibitors; pyrimidine derivatives
Prior art date: 2013-02-22

Application number

CY2022003C

Other languages

English (en)

Other versions

CY2022003I2 (el

Original Assignee

Pfizer Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-02-22

Filing date

2022-01-12

Publication date

2022-03-24

2022-01-12 Application filed by Pfizer Inc. filed Critical Pfizer Inc.

2022-03-24 Publication of CY2022003I1 publication Critical patent/CY2022003I1/el

2022-03-24 Publication of CY2022003I2 publication Critical patent/CY2022003I2/el

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Epidemiology (AREA)
Neurology (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Dermatology (AREA)
Oncology (AREA)
Psychiatry (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Ophthalmology & Optometry (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)
Communicable Diseases (AREA)

CY2022003C 2013-02-22 2022-01-12 Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις των σχετικων me janus (ιανος) kinασων (jak) CY2022003I2 (el)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201361767947P	2013-02-22	2013-02-22

Publications (2)

Publication Number	Publication Date
CY2022003I1 true CY2022003I1 (el)	2022-03-24
CY2022003I2 CY2022003I2 (el)	2022-03-24

Family

ID=50151346

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
CY20171101116T CY1119502T1 (el)	2013-02-22	2017-10-26	Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις των σχετικων me janus (ιανος) kinασων (jak)
CY20191100127T CY1121468T1 (el)	2013-02-22	2019-01-30	Συνδυασμος παραγωγων πυρρολο[2,3-d]πυριμιδινης με εναν ή περισσοτερους επιπροσθετους παραγοντες ως αναστολεις των σχετικων me janus (ιανος) kinασων (jak)
CY2022003C CY2022003I2 (el)	2013-02-22	2022-01-12	Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις των σχετικων me janus (ιανος) kinασων (jak)

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
CY20171101116T CY1119502T1 (el)	2013-02-22	2017-10-26	Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις των σχετικων me janus (ιανος) kinασων (jak)
CY20191100127T CY1121468T1 (el)	2013-02-22	2019-01-30	Συνδυασμος παραγωγων πυρρολο[2,3-d]πυριμιδινης με εναν ή περισσοτερους επιπροσθετους παραγοντες ως αναστολεις των σχετικων me janus (ιανος) kinασων (jak)

Country Status (47)

Country	Link
US (3)	US9035074B2 (el)
EP (2)	EP3290421B1 (el)
JP (2)	JP6145179B2 (el)
KR (1)	KR101787858B1 (el)
CN (2)	CN107089985B (el)
AP (1)	AP2015008664A0 (el)
AR (1)	AR094857A1 (el)
AU (1)	AU2014220357B2 (el)
BR (1)	BR112015019634B1 (el)
CA (1)	CA2900703C (el)
CL (1)	CL2015002303A1 (el)
CR (1)	CR20150395A (el)
CU (1)	CU24275B1 (el)
CY (3)	CY1119502T1 (el)
DK (2)	DK2958921T3 (el)
DO (1)	DOP2015000206A (el)
EA (1)	EA027879B1 (el)
ES (2)	ES2713052T3 (el)
FR (1)	FR22C1006I2 (el)
GE (1)	GEP201606600B (el)
HK (1)	HK1213881A1 (el)
HR (2)	HRP20171599T2 (el)
HU (3)	HUE037192T2 (el)
IL (1)	IL240132B (el)
LT (3)	LT2958921T (el)
MA (1)	MA38347A1 (el)
MD (1)	MD4735C1 (el)
ME (2)	ME03301B (el)
MX (1)	MX2015010928A (el)
MY (1)	MY177476A (el)
NL (1)	NL301155I2 (el)
NO (2)	NO3052752T3 (el)
NZ (1)	NZ710411A (el)
PE (1)	PE20151764A1 (el)
PH (1)	PH12015501779B1 (el)
PL (2)	PL3290421T3 (el)
PT (2)	PT3290421T (el)
RS (2)	RS58245B1 (el)
SG (1)	SG11201505816UA (el)
SI (2)	SI3290421T1 (el)
TN (1)	TN2015000355A1 (el)
TR (1)	TR201902525T4 (el)
TW (1)	TWI507408B (el)
UA (1)	UA111804C2 (el)
UY (1)	UY35337A (el)
WO (1)	WO2014128591A1 (el)
ZA (1)	ZA201505454B (el)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE036240T2 (hu)	2010-08-18	2018-06-28	Samumed Llc	Diketonok és hidroxiketonok mint kateninszignálút-aktivátorok
EP2948134B1 (en)	2013-01-24	2020-03-04	Palvella Therapeutics, Inc.	Compositions for transdermal delivery of mtor inhibitors
DK2968249T3 (en)	2013-02-22	2019-03-04	Samumed Llc	GAMMA DIKETONS AS WNT / BETA-CATENIN SIGNAL ROAD ACTIVATORS
SG11201505816UA (en)	2013-02-22	2015-09-29	Pfizer	Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak)
ES2750655T3 (es) *	2014-08-12	2020-03-26	Pfizer	Derivados de pirrolo[2,3-d]pirimidina útiles para inhibir la Janus cinasa
MX368248B (es)	2014-08-20	2019-09-25	Samumed Llc	Gamma-dicetonas para tratamiento y prevencion de piel envejecida y arrugas.
US10174056B2 (en) *	2015-05-29	2019-01-08	Wuxi Fortune Pharmaceutical Co., Ltd	Substituted pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US11780848B2 (en)	2015-10-16	2023-10-10	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
MX2018004605A (es)	2015-10-16	2018-11-29	Abbvie Inc	Procesos para la preparacion de (3s,4r)-3-etil-4-(3h-imidazo-[1,2- a]-pirrolo-[2,3-e]-pirazin-8-il)-n-(2,2,2-trifluoroetil)-pirrolid in-1-carboxamida y formas en estado solido de la misma.
US10550126B2 (en)	2015-10-16	2020-02-04	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en)	2015-10-16	2022-06-21	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN106831779B (zh) *	2015-11-28	2019-07-19	南昌弘益药业有限公司	一类jak激酶抑制剂的新化合物
WO2017143014A1 (en) *	2016-02-16	2017-08-24	Brian Kim	Jak inhibitors and uses thereof
AU2018205253B2 (en)	2017-01-06	2022-01-13	Palvella Therapeutics, Inc.	Anhydrous compositions of mTOR inhibitors and methods of use
CN108794480A (zh) *	2017-04-28	2018-11-13	天津药物研究院有限公司	吡咯并嘧啶类化合物、其制备方法和用途
UA128288C2 (uk)	2018-03-08	2024-05-29	Інсайт Корпорейшн	СПОЛУКИ АМІНОПІРАЗИНДІОЛУ ЯК ІНГІБІТОРИ PI3K-<font face="Symbol">g</font>
US11046658B2 (en)	2018-07-02	2021-06-29	Incyte Corporation	Aminopyrazine derivatives as PI3K-γ inhibitors
WO2020010073A1 (en)	2018-07-02	2020-01-09	Palvella Therapeutics, Inc.	ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE
AU2019299666B2 (en)	2018-07-06	2024-07-11	Pfizer Inc.	Manufacturing process and intermediates for a pyrrolo(2,3- d)pyrimidine compound and use thereof
CA3118488A1 (en) *	2018-11-05	2020-05-14	Avista Pharma Solutions, Inc.	Chemical compounds
PT3915989T (pt) *	2019-01-30	2023-10-02	Felicamed Biotechnology Co Ltd	Inibidor de jak e método de preparação do mesmo
EP3924355A1 (en)	2019-02-15	2021-12-22	Pfizer Inc.	Crystalline pyrimidinyl-3,8-diazabicyclo[3.2.1]octanylmethanone compound and use thereof
US20220185816A1 (en)	2019-03-14	2022-06-16	Shanghai Synergy Pharmaceutical Sciences Co., Ltd	Jak kinase inhibitor, preparation method for same, and applications thereof in field of medicine
WO2020261041A1 (en) *	2019-06-27	2020-12-30	Glenmark Life Sciences Limited	Process for preparation of abrocitinib
EP4028007A1 (en)	2019-09-11	2022-07-20	Pfizer Inc.	Treatment of hidradenitis with jak inhibitors
MX2022012135A (es)	2020-04-04	2023-01-18	Pfizer	Métodos para tratar la enfermedad de coronavirus de 2019.
CN113637018A (zh)	2020-04-27	2021-11-12	苏州晶云药物科技股份有限公司	磺酰胺类化合物的晶型及其制备方法
BR112022021525A2 (pt) *	2020-05-28	2022-12-13	Pfizer	Derivados de pirrolo [2,3-d] pirimidina
JP2023544495A (ja) *	2020-09-11	2023-10-24	ガルデルマホールディングエスエー	新規ｊａｋ阻害剤化合物、その合成方法、及びその使用
IL304874A (en)	2021-02-02	2023-10-01	Pfizer	A protocol for the treatment of chronic hand eczema
WO2023014049A1 (ko) *	2021-08-02	2023-02-09	한국화학연구원	신규한 피롤로 피리미딘 유도체 화합물, 이의 제조방법, 및 이를 유효성분으로 포함하는 대사성 간질환의 예방 또는 치료용 약학적 조성물
CN118255769A (zh) *	2022-12-28	2024-06-28	格格巫（珠海）生物科技有限公司	一种立体异构体的制备方法及中间体

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3037980A (en)	1955-08-18	1962-06-05	Burroughs Wellcome Co	Pyrrolopyrimidine vasodilators and method of making them
KR19990067704A (ko)	1992-12-17	1999-08-25	디. 제이. 우드, 스피겔 알렌 제이	부신피질자극호르몬 유리인자 길항제로서의 피롤로피리미딘을함유하는 약학 조성물
JPH06329674A (ja)	1993-05-20	1994-11-29	Teijin Ltd	４―置換シクロヘキシルアミノ―ピロロ［２，３―ｄ］ピリミジン
JPH06329675A (ja)	1993-05-20	1994-11-29	Teijin Ltd	４―置換アルキルアミノ―ピロロ［２，３―ｄ］ピリミジン誘導体
JPH08134068A (ja)	1994-11-02	1996-05-28	Teijin Ltd	４―置換アルキルアミノ―ピロロ［２，３―ｄ］ピリミジン誘導体
US6051578A (en)	1996-02-12	2000-04-18	Pfizer Inc.	Pyrazolopyrimidines for treatment of CNS disorders
US6686366B1 (en)	1998-06-02	2004-02-03	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine A3 receptor and uses thereof
US6232320B1 (en)	1998-06-04	2001-05-15	Abbott Laboratories	Cell adhesion-inhibiting antiinflammatory compounds
PA8474101A1 (es)	1998-06-19	2000-09-29	Pfizer Prod Inc	Compuestos de pirrolo [2,3-d] pirimidina
JP4666762B2 (ja)	1998-06-19	2011-04-06	ファイザー・プロダクツ・インク	ピロロ［２．３−ｄ］ピリミジン化合物
CZ27399A3 (cs)	1999-01-26	2000-08-16	Ústav Experimentální Botaniky Av Čr	Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
EP1040831A3 (en)	1999-04-02	2003-05-02	Pfizer Products Inc.	Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
US6284766B1 (en)	1999-04-30	2001-09-04	Neurogen Corporation	9H-pyrimido [4,5-b] indole derivatives: CRF1 specific ligands
US6664252B2 (en)	1999-12-02	2003-12-16	Osi Pharmaceuticals, Inc.	4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
NZ518884A (en)	1999-12-10	2004-02-27	Pfizer Prod Inc	Pyrrolo[2,3-d]pyrimidine compounds
EP1244668B1 (en)	2000-01-07	2006-04-05	Universitaire Instelling Antwerpen	Purine derivatives, process for their preparation and use thereof
UA74370C2 (uk)	2000-06-26	2005-12-15	Пфайзер Продактс Інк.	Піроло(2,3-d)піримідинові сполуки як імуносупресори
US6680324B2 (en)	2000-12-01	2004-01-20	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine A1 receptors and uses thereof
US6673802B2 (en)	2000-12-01	2004-01-06	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine A3 receptor and uses thereof
US7301023B2 (en)	2001-05-31	2007-11-27	Pfizer Inc.	Chiral salt resolution
AU2002360436A1 (en)	2001-11-30	2003-06-17	Osi Pharmaceuticals, Inc.	2-aryl pyrrologpyrimidines for a1 and a3 receptors
US20030139427A1 (en)	2002-08-23	2003-07-24	Osi Pharmaceuticals Inc.	Bicyclic pyrimidinyl derivatives and methods of use thereof
WO2004032834A2 (en)	2002-10-04	2004-04-22	Merck & Co., Inc.	Thrombin inhibitors
KR100678800B1 (ko)	2002-11-21	2007-02-05	화이자 프로덕츠 인코포레이티드	3-아미노-피페리딘 유도체 및 그의 제조 방법
AR054416A1 (es)	2004-12-22	2007-06-27	Incyte Corp	Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
SG170783A1 (en) *	2005-07-29	2011-05-30	Pfizer Prod Inc	Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis
JP2007091649A (ja)	2005-09-29	2007-04-12	Taisho Pharmaceut Co Ltd	ピリミジン誘導体及びその使用に関連する治療方法
GB0526246D0 (en) *	2005-12-22	2006-02-01	Novartis Ag	Organic compounds
EP2007373A4 (en)	2006-03-29	2012-12-19	Foldrx Pharmaceuticals Inc	INHIBITION OF ALPHA SYNUCLEINE TOXICITY
US20080200458A1 (en)	2007-01-18	2008-08-21	Joseph Barbosa	Methods and compositions for the treatment of body composition disorders
WO2008089307A2 (en)	2007-01-18	2008-07-24	Lexicon Pharmaceuticals, Inc.	Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
BRPI0820342A2 (pt)	2007-11-07	2015-05-26	Foldrx Pharmaceuticals Inc	Modulação de tráfego de proteína
AU2008326184A1 (en)	2007-11-08	2009-05-14	Pfizer Inc.	Cyclobutyl carboxylic acid derivatives
US8946239B2 (en)	2008-07-10	2015-02-03	Duquesne University Of The Holy Spirit	Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
AU2009283844B2 (en)	2008-08-20	2013-09-05	Zoetis Services Llc	Pyrrolo[2,3-d]pyrimidine compounds
PE20110793A1 (es)	2008-09-18	2011-10-31	Pfizer Ltd	Derivados de (3-(4-cianofenil)-1h-pirazol-5 carboxamida como antagonistas del receptor de progesterona
PE20121077A1 (es) *	2009-10-15	2012-08-10	Pfizer	Compuestos de pirrolo[2,3-d]pirimidina
RU2711869C3 (ru)	2009-12-01	2022-02-02	Эббви Инк.	Имидазопирролопиразиновые производные, полезные для лечения заболеваний, вызванных аномальной активностью протеинкиназ Jak1, Jak3 или Syk
WO2011075334A1 (en)	2009-12-18	2011-06-23	Pfizer Inc.	Pyrrolo[2,3-d]pyrimidine compounds
TW201129565A (en)	2010-01-12	2011-09-01	Hoffmann La Roche	Tricyclic heterocyclic compounds, compositions and methods of use thereof
CN104224737A (zh)	2010-02-24	2014-12-24	硕腾有限责任公司	兽医组合物
CN103097340B (zh)	2010-07-16	2018-03-16	安吉奥斯医药品有限公司	治疗活性组合物及其使用方法
WO2012009649A1 (en)	2010-07-16	2012-01-19	Anderson Gaweco	Mif inhibitors and their uses
MX2013006251A (es)	2010-12-03	2013-10-01	Epizyme Inc	Compuestos de purina y 7 - deazapurina substituidos como moduladores de enzimas epigeneticas.
US8987307B2 (en)	2011-03-03	2015-03-24	Hoffmann-La Roche Inc.	3-amino-pyridines as GPBAR1 agonists
MX2013014427A (es)	2011-06-07	2014-01-23	Dainippon Sumitomo Pharma Co	Derivado de indazol y pirrolopiridina y uso farmaceutico del mismo.
JP2013010719A (ja)	2011-06-30	2013-01-17	Dainippon Sumitomo Pharma Co Ltd	ベンズイミダゾロンおよびオキシインドール誘導体ならびにそれらの医薬用途
US9527851B2 (en) *	2011-12-21	2016-12-27	Jiangsu Hengrui Medicine Co., Ltd.	Pyrrole six-membered heteroaryl ring derivative, preparation method thereof, and medicinal uses thereof
US20140018361A1 (en)	2012-07-11	2014-01-16	Nimbus Iris, Inc.	Irak inhibitors and uses thereof
MX360857B (es)	2012-07-20	2018-11-20	Zoetis Llc	Régimen de dosificación para inhibidores de janus quinasa (jak).
JP2014133739A (ja)	2012-12-12	2014-07-24	Dainippon Sumitomo Pharma Co Ltd	インダゾール誘導体またはピロロピリジン誘導体からなる医薬
SG11201505816UA (en) *	2013-02-22	2015-09-29	Pfizer	Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak)
ES2750655T3 (es)	2014-08-12	2020-03-26	Pfizer	Derivados de pirrolo[2,3-d]pirimidina útiles para inhibir la Janus cinasa

2014
- 2014-02-11 SG SG11201505816UA patent/SG11201505816UA/en unknown
- 2014-02-11 CA CA2900703A patent/CA2900703C/en active Active
- 2014-02-11 RS RS20190097A patent/RS58245B1/sr unknown
- 2014-02-11 HU HUE14705887A patent/HUE037192T2/hu unknown
- 2014-02-11 MA MA38347A patent/MA38347A1/fr unknown
- 2014-02-11 LT LTEP14705887.9T patent/LT2958921T/lt unknown
- 2014-02-11 MD MDA20150073A patent/MD4735C1/ro active IP Right Grant
- 2014-02-11 EA EA201591255A patent/EA027879B1/ru unknown
- 2014-02-11 RS RS20171095A patent/RS56503B1/sr unknown
- 2014-02-11 AP AP2015008664A patent/AP2015008664A0/xx unknown
- 2014-02-11 JP JP2015558572A patent/JP6145179B2/ja active Active
- 2014-02-11 ES ES17191163T patent/ES2713052T3/es active Active
- 2014-02-11 PT PT17191163T patent/PT3290421T/pt unknown
- 2014-02-11 HU HUE17191163A patent/HUE041778T2/hu unknown
- 2014-02-11 NZ NZ710411A patent/NZ710411A/en unknown
- 2014-02-11 SI SI201431068T patent/SI3290421T1/sl unknown
- 2014-02-11 CN CN201710440379.1A patent/CN107089985B/zh active Active
- 2014-02-11 ME MEP-2019-6A patent/ME03301B/me unknown
- 2014-02-11 CN CN201480009783.8A patent/CN105008362B/zh active Active
- 2014-02-11 TR TR2019/02525T patent/TR201902525T4/tr unknown
- 2014-02-11 DK DK14705887.9T patent/DK2958921T3/da active
- 2014-02-11 ME MEP-2017-246A patent/ME02904B/me unknown
- 2014-02-11 SI SI201430459T patent/SI2958921T1/sl unknown
- 2014-02-11 GE GEAP201413916A patent/GEP201606600B/en unknown
- 2014-02-11 ES ES14705887.9T patent/ES2647525T3/es active Active
- 2014-02-11 PT PT147058879T patent/PT2958921T/pt unknown
- 2014-02-11 PL PL17191163T patent/PL3290421T3/pl unknown
- 2014-02-11 MY MYPI2015702431A patent/MY177476A/en unknown
- 2014-02-11 EP EP17191163.9A patent/EP3290421B1/en active Active
- 2014-02-11 LT LTEP17191163.9T patent/LT3290421T/lt unknown
- 2014-02-11 PE PE2015001766A patent/PE20151764A1/es active IP Right Grant
- 2014-02-11 PL PL14705887T patent/PL2958921T3/pl unknown
- 2014-02-11 WO PCT/IB2014/058889 patent/WO2014128591A1/en active Application Filing
- 2014-02-11 BR BR112015019634-9A patent/BR112015019634B1/pt active IP Right Grant
- 2014-02-11 DK DK17191163.9T patent/DK3290421T3/en active
- 2014-02-11 CU CUP2015000078A patent/CU24275B1/xx unknown
- 2014-02-11 AU AU2014220357A patent/AU2014220357B2/en active Active
- 2014-02-11 MX MX2015010928A patent/MX2015010928A/es active IP Right Grant
- 2014-02-11 EP EP14705887.9A patent/EP2958921B1/en active Active
- 2014-02-11 KR KR1020157022489A patent/KR101787858B1/ko active IP Right Grant
- 2014-02-19 TW TW103105469A patent/TWI507408B/zh active
- 2014-02-19 US US14/183,946 patent/US9035074B2/en active Active
- 2014-02-20 UY UY0001035337A patent/UY35337A/es not_active Application Discontinuation
- 2014-02-21 AR ARP140100561A patent/AR094857A1/es active IP Right Grant
- 2014-09-24 NO NO14789648A patent/NO3052752T3/no unknown
- 2014-11-02 UA UAA201507511A patent/UA111804C2/uk unknown
2015
- 2015-04-21 US US14/691,606 patent/US9545405B2/en active Active
- 2015-05-18 US US14/715,046 patent/US9549929B2/en active Active
- 2015-07-23 IL IL240132A patent/IL240132B/en active IP Right Grant
- 2015-07-29 ZA ZA2015/05454A patent/ZA201505454B/en unknown
- 2015-07-30 CR CR20150395A patent/CR20150395A/es unknown
- 2015-08-12 PH PH12015501779A patent/PH12015501779B1/en unknown
- 2015-08-17 CL CL2015002303A patent/CL2015002303A1/es unknown
- 2015-08-18 TN TN2015000355A patent/TN2015000355A1/fr unknown
- 2015-08-21 DO DO2015000206A patent/DOP2015000206A/es unknown
2016
- 2016-02-18 HK HK16101741.2A patent/HK1213881A1/zh unknown
2017
- 2017-05-11 JP JP2017094676A patent/JP2017165762A/ja active Pending
- 2017-10-19 HR HRP20171599TT patent/HRP20171599T2/hr unknown
- 2017-10-26 CY CY20171101116T patent/CY1119502T1/el unknown
2019
- 2019-01-23 HR HRP20190152TT patent/HRP20190152T1/hr unknown
- 2019-01-30 CY CY20191100127T patent/CY1121468T1/el unknown
2021
- 2021-12-22 NL NL301155C patent/NL301155I2/nl unknown
2022
- 2022-01-12 CY CY2022003C patent/CY2022003I2/el unknown
- 2022-01-17 HU HUS2200003C patent/HUS2200003I1/hu unknown
- 2022-01-26 LT LTPA2022502C patent/LTPA2022502I1/lt unknown
- 2022-02-01 NO NO2022004C patent/NO2022004I1/no unknown
- 2022-02-10 FR FR22C1006C patent/FR22C1006I2/fr active Active

Also Published As

Publication number	Publication date
CN107089985B (zh)	2019-06-07
SI2958921T1 (sl)	2017-12-29
SI3290421T1 (sl)	2019-03-29
CY1119502T1 (el)	2018-03-07
CY2022003I2 (el)	2022-03-24
JP6145179B2 (ja)	2017-06-07
AR094857A1 (es)	2015-09-02
US9035074B2 (en)	2015-05-19
HK1213881A1 (zh)	2016-07-15
PT3290421T (pt)	2019-03-01
NL301155I1 (el)	2021-12-22
EP2958921A1 (en)	2015-12-30
PL2958921T3 (pl)	2018-01-31
RS56503B1 (sr)	2018-02-28
HUS2200003I1 (hu)	2022-02-28
MA38347A1 (fr)	2017-10-31
ES2713052T3 (es)	2019-05-17
UA111804C2 (uk)	2016-06-10
US20150225408A1 (en)	2015-08-13
BR112015019634A2 (pt)	2019-12-17
HRP20190152T1 (hr)	2019-03-22
ME02904B (me)	2018-04-20
FR22C1006I1 (fr)	2022-03-25
HUE037192T2 (hu)	2018-08-28
DK2958921T3 (da)	2017-11-06
US9545405B2 (en)	2017-01-17
MD20150073A2 (ro)	2016-01-31
WO2014128591A1 (en)	2014-08-28
ES2647525T3 (es)	2017-12-22
TW201443055A (zh)	2014-11-16
AU2014220357A1 (en)	2015-08-06
CA2900703C (en)	2017-11-28
NO2022004I1 (no)	2022-02-01
PE20151764A1 (es)	2015-12-03
US20150246048A1 (en)	2015-09-03
MD4735C1 (ro)	2021-07-31
CR20150395A (es)	2015-09-23
JP2017165762A (ja)	2017-09-21
LTPA2022502I1 (el)	2022-03-10
UY35337A (es)	2014-09-30
GEP201606600B (en)	2017-01-10
NO3052752T3 (el)	2018-06-16
LT3290421T (lt)	2019-02-25
KR20150109434A (ko)	2015-10-01
HUE041778T2 (hu)	2019-05-28
PL3290421T3 (pl)	2019-05-31
FR22C1006I2 (fr)	2023-01-27
AP2015008664A0 (en)	2015-08-31
MD4735B1 (ro)	2020-12-31
CL2015002303A1 (es)	2015-12-18
AU2014220357B2 (en)	2017-04-27
KR101787858B1 (ko)	2017-10-18
ZA201505454B (en)	2016-07-27
CA2900703A1 (en)	2014-08-28
CN107089985A (zh)	2017-08-25
MX2015010928A (es)	2015-10-29
MY177476A (en)	2020-09-16
LT2958921T (lt)	2017-11-27
TR201902525T4 (tr)	2019-03-21
IL240132A0 (en)	2015-09-24
BR112015019634B1 (pt)	2022-09-20
US20140243312A1 (en)	2014-08-28
DK3290421T3 (en)	2019-03-18
DOP2015000206A (es)	2016-02-15
HRP20171599T1 (hr)	2017-12-01
CN105008362B (zh)	2017-06-06
EP3290421B1 (en)	2019-01-02
IL240132B (en)	2020-09-30
HRP20171599T2 (hr)	2018-11-16
TN2015000355A1 (fr)	2017-01-03
NZ710411A (en)	2017-11-24
CY1121468T1 (el)	2020-05-29
TWI507408B (zh)	2015-11-11
NL301155I2 (nl)	2022-02-23
PT2958921T (pt)	2017-11-20
SG11201505816UA (en)	2015-09-29
US9549929B2 (en)	2017-01-24
PH12015501779A1 (en)	2015-12-02
EA201591255A1 (ru)	2016-03-31
CU24275B1 (es)	2017-10-05
CU20150078A7 (es)	2016-01-29
CN105008362A (zh)	2015-10-28
ME03301B (me)	2019-07-20
RS58245B1 (sr)	2019-03-29
EP2958921B1 (en)	2017-09-20
EP3290421A1 (en)	2018-03-07
JP2016509049A (ja)	2016-03-24
PH12015501779B1 (en)	2015-12-02
EA027879B1 (ru)	2017-09-29

Publication	Publication Date	Title
CY2022003I1 (el)	2022-03-24	Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις των σχετικων me janus (ιανος) kinασων (jak)
DK3808749T3 (da)	2023-06-06	Pyrazolo[1,5-a]pyrimidiner, der er nyttige som inhibitorer af atr-kinase til behandling af kræftsygdomme
SG11201600062RA (en)	2016-02-26	Pyrimidine derivatives as kinase inhibitors
CO6801740A2 (es)	2013-11-29	Inhibidores de quinasa relacionados con pirrolo[2,3-d]pirimidina tropomiosina
EP2981535B8 (en)	2021-03-10	Urea derivatives useful as kinase inhibitors
EP2976338A4 (en)	2016-08-31	N- (2-CYANO-HETEROCYCLYL) PYRAZOLO-PYRIDONES AS INHIBITORS OF JANUS KINASE
HK1222386A1 (zh)	2017-06-30	作爲詹納斯激酶的抑制劑的 -氰基甲基酰胺
ME02551B (me)	2017-02-20	Novi derivati pirimidina kao inhibitori fosfodiesteraze 10 (pde- 10)